CompletedNCT04235686
MYDAYIS for Depression in Bipolarity: Phase 2 Study
About this title
8 Week Multi-site Study of MYDAYIS® for Bipolar Depression
Read the official source — NCT04235686Medication studyAges 18–55United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Rochester and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 17, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 74
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04235686
- Official title
Show the full official title
An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Rochester · Mason
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Mydayis Extended-Release Capsule and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
